Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


MassMutual makes up $100m SEA fund
MassMutual Ventures has followed up on the $50m Southeast Asian fund it launched in late 2018 with a second vehicle dedicated to the region.
I-Mab enters public markets in $104m IPO
The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.
Concerto HealthAI codifies $150m in series B round
SymphonyAI Group has taken part in a $150m round for one of its spinoffs, precision cancer therapy developer Concerto HealthAI.
D2SF takes care of new investments
Naver has backed four health and education technology developers – Huray Positive, Ichrogene, N.Cer and SoundGym – through its D2 Startup Factory accelerator.
Corporate venturing deal net: 13-17 January 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Emendo imports $61m in series B funding
Takeda Ventures converted debt financing into equity through the genetic medicine developer's latest round, which was led by strategic partner AnGes.
UPMC Enterprises to deploy $1bn
University of Pittsburgh Medical Center’s investment and innovation arm has allocated $1bn to drug development funding over the next four years.
CareBridge takes the weight of $40m
GV was among the investors as long-term care support provider CareBridge emerged from stealth with $40m and two acquisitions.

Other News

Launchpad Digital Health enlarges second fund
Wilson Sonsini Goodrich & Rosati and an undisclosed insurer are among the LPs for the venture firm's new digital health-focused vehicle.
Zelgen sells Shanghai on $294m IPO
Minsheng Life-backed oncology drug developer Zelgen has priced an initial public offering set to value it at more than $1.1bn.
Cigna Ventures signs off on two new deals
Cigna's corporate venturing arm led a $29.5m round for population healthcare management platform and bumped Buoy Health's series B up to $20m.
Vesta Healthcare rests series A with $30m
CareCentrix, Nationwide and existing backer Kaiser Permanente all chipped in as the homecare support services provider secured $30m.
Bigfoot Medical steps into $45m series C
Abbott has returned for the first close of insulin technology developer Bigfoot Biomedical’s series C round, after backing its $55m series B two years ago.
EQRx exits stealth with $200m
GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

Editor's Picks

Vertex veers to Semma for $950m acquisition
Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.
Carroll retires from Lilly after two decades
After 22 years at Eli Lilly that included laying the groundwork for its corporate venturing activities, senior vice-president of corporate business development Darren Carroll is retiring.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
test reg